Abbott Labs (NYSE:ABT) and Mylan (NASDAQ:MYL) gave investors reason to cheer today. Mylan bought up Abbott's established pharmaceuticals portfolio in non-emerging, ex-U.S. markets for $5.3 billion in an all-stock deal.

Was it a good idea for Mylan shareholders?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.